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KCNH2-encoded hERG1 channels conduct the rapid delayed rectifier potassium current (IKr), 
which plays a vital role in controlling the duration of cardiac action potentials. Ever since the 
importance of hERG1 currents in regulating cardiac repolarization was first demonstrated, 
there has been considerable interest in the pharmacological manipulation of these 
channels. In their paper, Sale et al. (2017) have characterized the properties of a structurally 
and functionally novel hERG activator, ITP-2, which dramatically increases hERG1 current 
amplitudes. 
Long before hERG1 activators became available, selective hERG1 channel blockers were 
developed as class III antiarrhythmic drugs to prolong refractory periods and treat re-
entrant arrhythmias. However, post-marketing surveillance and then clinical trials revealed 
that selective hERG1 channel inhibitors could produce excessive prolongation of 
repolarization and, thereby, be pro-arrhythmic. Subsequent work found that hERG1 
channels are also sensitive to pharmacological inhibition by diverse non-cardiac drugs (see 
Vandenberg et al., 2012), and this is one of the main causes of drug-induced long QT 
syndrome (LQTS). Genetically inherited loss-of-function hERG1 mutations that reduce 
hERG1 channel function, through either altered kinetics or impaired trafficking, have also 
been linked to inherited LQTS (LQTS2) and a greatly increased risk of ventricular fibrillation 
and sudden death. Gain-of-function hERG1 mutations have also been identified that cause 
an excessive shortening of QT interval and also carry an increased risk of ventricular 
fibrillation and sudden death. This has led to the ‘Goldilocks’ principle in which the 
magnitude and timing of repolarizing hERG currents need to be ‘just right’. 
The unique and complex gating properties of hERG underlie its crucial role in cardiac action 
potential repolarization. hERG gating is characterized by a very rapid and voltage-dependent 
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form of inactivation, which unusually is faster than activation gating. During the early part of 
the action potential, hERG current magnitude is small because the channels activate slowly 
and most have rapidly inactivated. However, once repolarization starts, the channels quickly 
recover from inactivation, resulting in a rapid increase in hERG amplitude that plays a 
central role in timing the end of the plateau phase of the action potential. hERG channels 
also deactivate slowly ensuring they remain open to contribute to final repolarization and 
also oppose undesirable premature depolarizations. 
Inherited LQTS can result not only from mutations to hERG1 but also a variety of other 
cardiac genes. Seventeen different LQTS-associated genes have been identified – most of 
which encode ion channel subunits (Campuzano et al., 2015). LQTS is one of the most 
common genetic diseases and affects an estimated 1 in 5000 to 10 000 people worldwide 
and is a particularly significant cause of sudden death among young people. hERG1 channel 
activators (or agonists) are compounds that increase the amplitude of hERG1 currents. At 
least in principle, hERG1 activators have therapeutic potential for reducing the risk of 
sudden death in LQTS patients by increasing the amount of repolarizing K+ current during 
the cardiac action potential (Grunnet, 2010). 
The pharmaceutical industry has made tremendous progress in identifying compounds early 
in development that have the potential to cause the drug-induced form of LQTS. This has 
been facilitated by the advent of new medium throughput electrophysiology platforms that 
make it feasible to test large numbers of compounds for their potential to block hERG1 
channels. Ironically, the identification of hERG1 activators has predominantly come from 
efforts to screen out hERG1 blockers. 
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Three main groups of compounds with the ability to increase hERG1 current amplitudes 
have been described, based primarily on their mechanisms of function and, to a lesser 
extent, on their putative site of action (Perry et al., 2010). Type 1 activators enhance current 
primarily by profoundly slowing channel closure (deactivation). These activators bind to 
sites on the cytoplasmic end of the pore, at sites facing away from the conduction pathway 
and inner cavity of the channel. They constrain movements of the activation gate and delay 
closure of the channel. Type 1 activators may also reduce channel inactivation, but that is 
not their major mechanism of action. Type 2 activators on the other hand predominantly 
exert their effects by causing large positive shifts of the voltage dependence of inactivation 
and by slowing the onset of inactivation, resulting in a large increase of channel open 
probability at depolarized potentials. Mutagenesis and molecular modelling studies suggest 
these activators are likely to bind to sites close to the selectivity filter on the extracellular 
side of the pore. They may stabilize the open conformation of the selectivity filter or alter 
the ability of the voltage sensor to interact with the pore and induce inactivation. The types 
1 and 2 classification of activators should probably be extended to include a third type that 
enhance hERG1 currents by accelerating activation and shifting its voltage dependence to 
more negative potentials. An example is KB130015, a derivative of the hERG blocker 
amiodarone. KB130015 is likely to bind within the inner cavity since it competes with 
amiodarone and other blockers that are known to bind at this pore location. Another group 
of compounds that also cause negative shifts of the voltage dependence of activation is 
referred to as facilitators because while they enhance hERG1 currents with weak 
depolarizations, they inhibit currents elicited by stronger depolarizations. Facillitators also 
appear to exert their actions from the intracellular side of the channel, often compete with 
5 
 
pore channel blockers and are less effective when inner cavity sites are mutated. All of these 
effects are consistent with a binding site within the inner cavity. 
ITP-2, the compound characterized by Sale et al. (2017), is interesting because it is more 
potent than most of the previously described activators (EC50 of 1 μM) and because its 
mechanism of action is distinct from the different types of activators described above, 
combining properties of the last two groups with some further unique features of its own. 
During conventional two-step I–V protocols, ITP-2 enhanced hERG1 currents during the first 
test pulse at all potentials from −60 to +60 mV, but surprisingly, the tail currents measured 
upon repolarization to −65 mV were profoundly inhibited following most test pulses. The 
mechanism for the enhanced currents during the test pulses is likely to be a combination of 
attenuated inactivation and increased activation. Both gating processes have shifts in the 
voltage and time-dependent kinetics that would lead to an increase of current amplitudes 
during the test pulses. The mechanism for the attenuated tail currents is much less clear. 
There is no change of reversal potential, and so, an intriguing possibility that warrants 
further investigation is that the compound has a second binding site that leads to channel 
block. There are several pieces of evidence that support this conclusion, including that the 
concentration response relationship is bell-shaped (with less activation at 10 μM than at 
3 μM) and that for several mutants that disrupt inactivation gating, the current activation is 
absent, but the inhibitory effect remains. What is clear is that despite the attenuated 
currents at negative potentials, the overall effect of ITP-2 during a cardiac action potential is 
a substantial increase of current during a cardiac ventricular action potential that would be 
expected to shorten repolarization times. However, it should be noted that during late 
repolarization and post-repolarization phases, ITP-2 may actually reduce hERG1 channel 
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currents, increasing vulnerability to unwanted premature depolarizations. This is the 
opposite outcome of what would be aimed for in developing an antiarrhythmic drug. 
Another very interesting finding of this study is that heteromeric hERG1a/1b channels are 
much less sensitive to the ITP-2 activator effect than homomeric hERG1a channels. From a 
therapeutic potential, this is important because there is clear evidence that native cardiac 
tissues express both the full length hERG1a transcript and the shorter hERG1b variant. 
Functional data demonstrate that heteromeric hERG1a/1b channels mediate cardiac IKr. 
From a pharmacological perspective, ITP-2 is one of a small, but steadily increasing, number 
of compounds that show different effects on channels containing hERG1b subunits. 
Understanding the molecular basis for this could be very beneficial in a number of clinical 
settings, including the treatment of hERG1b containing cancers or forms of hERG-associated 
LQTS where a complex situation could arise because of the presence of both wild-type and 
mutant hERG1a/1b subunits. The only structural difference between the 1a and 1b proteins 
lies in the amino terminus, which interacts with the pore and voltage-sensing domains from 
the intracellular side of the membrane and is unique and much smaller in the hERG1b 
variant. The amino acid sequences of the transmembrane domains are identical. The 
authors show that ITP-2 mediates its effects on hERG1a from the extracellular side of the 
membrane, and thus, it seems likely that the amino terminus has an allosteric effect on the 
ITP-2 activation binding site. 
The paper by Sale et al. (2017) contains a wealth of information and mechanistic insight, but 
clearly, further investigations of this fascinating compound are merited. We do not yet know 
its selectivity for hERG1, relative to other ion channels. Investigations of its antiarrhythmic 
potential in cardiac preparations are also required. Understanding more about where it 
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binds and how it modulates hERG1 channel activity could be useful for the development of 
higher efficacy IKr activators with an improved set of properties for treating cardiac 
arrhythmias. 
Nomenclature of targets and ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Southan et al., 2016), and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015). 
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